Introduction
Developmental eye anomalies, including anophthalmia, microphthalmia, and coloboma (AMC), are a genetically heterogeneous group of disorders affecting around 30 per 100,000 live births (Campbell et al. 2002) . A rapidly growing number of genes have been identified for these anomalies, including SOX2 (Fantes et al. 2003) , OTX2 (Ragge et al. 2005) , and BMP4 (Bakrania et al. 2008) . Following the identification of a de novo 19p13.2 microdeletion involving OLFM2 in an individual with bilateral Abstract Anophthalmia, microphthalmia, and coloboma are a genetically heterogeneous spectrum of developmental eye disorders and affect around 30 per 100,000 live births. OLFM2 encodes a secreted glycoprotein belonging to the noelin family of olfactomedin domain-containing proteins that modulate the timing of neuronal differentiation during development. OLFM2 SNPs have been associated with open angle glaucoma in a case-control study, and knockdown of Olfm2 in zebrafish results in reduced eye size. From a cohort of 258 individuals with developmental eye anomalies, we identified two with heterozygous variants in OLFM2: an individual with bilateral microphthalmia carrying a de novo 19p13.2 microdeletion involving OLFM2 and a second individual with unilateral microphthalmia and contralateral coloboma who had a novel single base change in the 5′ untranslated region. Dual luciferase assays demonstrated that the latter variant causes a significant decrease in Electronic supplementary material The online version of this article (doi:10.1007/s00439-016-1745-8) contains supplementary material, which is available to authorized users. microphthalmia, we investigated the role of this gene in developmental eye disorders.
Single nucleotide polymorphisms (SNPs) in OLFM2 have been previously associated with open angle glaucoma (Funayama et al. 2006) . OLFM2 has a 31% homology to MYOC (Myocilin), mutations of which account for 3-4% of primary open angle glaucoma and a significant proportion of juvenile open angle glaucoma (Mukhopadhyay et al. 2004) .
OLFM2 encodes a secreted glycoprotein belonging to the noelin family of olfactomedin domain-containing proteins that modulate the timing of neuronal differentiation during development (Gautier et al. 2009; Tomarev and Nakaya 2009) . OLFM2 is present in the nucleus and is predicted to contain a DNA-binding domain and may play a role as a transcriptional coactivator (Shi et al. 2014) . It is expressed in human (Mukhopadhyay et al. 2004) , mouse (Sultana et al. 2011) , and zebrafish eyes, and zebrafish knockdowns exhibiting an average 24% decrease in eye area (Lee et al. 2008 ). This reduction is possibly mediated by decreased expression of Pax6, which is observed in zebrafish Olfm2 knockdowns (Lee et al. 2008) . Heterozygous mutations in PAX6 cause aniridia, Peters' anomaly, foveal hypoplasia, keratitis, cataract, coloboma, and microphthalmia (OMIM #607108). OLFM2 may play a role in TGFβ signaling, which includes BMP4, during early eye development, since OLFM2 expression has been shown to increase after TGFβ induction in human embryonic stem cell-derived mesenchymal cells (Shi et al. 2014) .
In addition to eye size, Olfm2 zebrafish knockdowns show altered nervous system development, including optic tectum, defects of the midbrain-hindbrain boundary, and altered axonal trajectories and extension (Lee et al. 2008 ). Interestingly, a distinct cutoff in OTX2 expression at the midbrain-hindbrain boundary is observed in the human embryo at CS14 (Ragge et al. 2005) . Expression of Olfm2 is initially present in the entire zebrafish eye, becoming increasingly localised to the retinal ganglion cell layer as development progresses.
Therefore, OLFM2 represents an excellent candidate gene for AMC. We describe an individual with bilateral microphthalmia and a de novo deletion on chromosome 19p13.2 affecting OLFM2 and COL5A3. We screened OLFM2 for variants in 258 patients with developmental eye anomalies, identifying a second individual with a 5′ untranslated region (UTR) variant that decreases OLFM2 expression. We demonstrate expression of OLFM2 in early human embryonic tissue, including the optic cup and lens vesicle.
Materials and methods

Cohort description
A UK cohort with ocular anomalies, principally AMC, was recruited as part of a national 'Genetics of Eye and Brain anomalies' study (REC study number 04/Q0104/129). Patients were screened by indication in known AMC genes. From this cohort, 258 individuals without a genetic diagnosis were screened for variants in OLFM2. Of these, 32 individuals had bilateral anophthalmia or unilateral anophthalmia with contralateral microphthalmia, 43 had bilateral microphthalmia (±coloboma), 146 had unilateral anophthalmia/microphthalmia (±contralateral defects), and 37 had other phenotypes, including anterior segment dysgenesis.
Array CGH
Array CGH was performed using the Agilent (USA) 44 K oligonucleotide platform (design 017457), as previously described (Ahn et al. 2010 ).
Mutation analysis
All six coding exons of OLFM2 (NM_058164.3), the alternate first exon of NM_001304348.1, and flanking sequences were screened for mutations by high-resolution melting curve analysis on a LightScanner (Idaho Technology) followed by Sanger sequencing of samples with aberrant melting curves (see Supplementary Methods and Supplementary Table 1 for detailed description) and sequence data analysed using CodonCode Aligner (CodonCode Corporation, Dedham, MA) or Chromas (Technelysium).
Gene panel sequencing
Next-generation sequencing was performed for Case 1 using a custom-designed Nextera-based chemistry (Illumina) panel of 546 genes divided between 351 known eye disorder genes and 195 candidate genes, selected from animal models, pathophysiological pathways, and preliminary studies. Sequencing was performed using a custom-designed Nextera-based chemistry (Illumina) containing in excess of 10,225 probes targeting 1,380,306 bp. Sequence capture, sample barcoding, and pre-enrichment sample pooling were performed according to manufacturer's instructions (Illumina) and paired-end sequencing performed on the MiSeq-sequencing platform (Illumina). Sequences were aligned to the reference human genome (UCSC hg19) using BWA-MEM (http://bio-bwa.sourceforge.net/) and Novoalign v3.01.00 (Novocraft). The mean coverage was 230x. Identified variants were filtered based on sequence quality, minor allele frequency, and predicted effect. Filters were applied to remove variants with low quality ('scThreshold': 0.94999999999999996, 'abThreshold': 0.001, 'minMapQual': 20, 'minBaseQual': 20, 'badReadsThreshold': 20, and 'hapScoreThreshold': 4) . In addition, all synonymous variants and those with a frequency of at least 1% in the 1000 Genomes Project database or those which occurred in multiple patients run on this custom panel were removed.
Transcription factor-binding bioinformatical analysis
Potential effects of the c.-57C>G OLFM2 5′ UTR variant were examined using the online program TFbind (http:// tfbind.hgc.jp/) (Tsunoda and Takagi 1999) . Sequences containing the wild type and variant alleles plus 15 bases of flanking sequencing were used as input data, and the program run using default settings.
RNA in situ hybridisation
Nonradioactive RNA in situ hybridisation was performed on human embryo sections at Carnegie Stages (CS) 15 and 17 as described elsewhere (Bakrania et al. 2008) . Probes were designed to span the end of the coding region and part of the 3′ UTR of the OLFM2 to bind all known splice variants and generated using the primers GCTCGGCGGCCGC TTCACGTCATCAGCACCTCT and GCTCGGTCGACTC CATGCACTCAACTCCTGG. Human embryos were obtained from the MRC/Wellcome Trust Human Developmental Biology Resource, UCL, with full ethical approval.
Cell culture and cDNA generation Y79 (human retinoblastoma) cells were cultured in RPMI1640 media supplemented with 10 mmol HEPES, 1 mmol sodium pyruvate, 4.5 g/L glucose, 2 mmol l-glutamine, 20 U/ml penicillin, and 0.1 mg/ml streptomycin and 20% fetal bovine serum (Sigma, Gillingham, UK). Cells were cultured at 37 °C and 5% CO 2 . RNA was extracted using the RNeasy Mini Kit (Qiagen, UK). cDNA was generated using the QuantiTect Reverse Transcription kit (Qiagen).
cDNA PCR
Primers were designed to span the unannotated 5′ UTR variant (Supplementary Table 2 ). PCRs were performed using 1:10 diluted cDNA, 1X HotShot™ Mastermix (Cadama Medical), 10% v/v DMSO (Sigma), and 0.25 μM of each primer in a final volume of 10 μl. PCRs were for 35 cycles and used a 55 °C annealing temperature. OLFM2 expression was confirmed using a second PCR with primers for exon 6 that were also used for the LightScanner analysis (Supplementary Table 2 ).
Dual luciferase assays
Constructs were generated to incorporate the unannotated OLFM2 5′ UTR (NM_058164.3) variant from Case 2 (primers: GCTCGGGTACCGCAACAAAGACTCGG AGCG and GCTCGGAGCTCCGTGAGCGGCCACATG AC) and cloned in the pGL3-Promoter vector (Promega). Vectors containing wild type and variant inserts were identified by Sanger sequencing, cultured overnight, and DNA extracted.
Transfections were performed using plasmids containing wild type, mutant, or no insert. Normalisation was performed using pRL-TK plasmids (Promega). Per reaction, 2.5 µg plasmid was diluted in 500 µl Opti-MEM ® I Reduced Serum Medium (Gibco) and 5 µl Plus™ Reagent (Invitrogen), incubated at room temperature for 15 min, 5 µl Lipofectamine ® LTX Reagent (Invitrogen) added, and incubated for 15 min at room temperature. 500 µl plasmid/lipofectamine mix was added to each well containing 3 × 10 5 Y79 cells in 2 ml RPMI1640 media (Sigma) and incubated at 37 °C overnight. Cell lysates were obtained using Passive Lysis Buffer (PLB) (Promega) (manufacturer's instructions), resuspended in 60 µl PLB, and stored at −80 °C. Assays were performed using the Dual-Luciferase Reporter Assay System (Promega) (manufacturer's instructions) and measured on a MicroBeta TriLux using the Micro Beta Windows Workstation software (PerkinElmer).
Results
Case 1
A male infant was born to non-consanguineous Caucasian parents by normal delivery at 41 weeks gestation weighing 3.046 kg following an uneventful pregnancy. He had apparently isolated bilateral mild microphthalmia with cloudy vascularised sclerocornea. There was a reasonable view to a normal right disc and retina and no fundal view on the left. Cranial ultrasound examination was normal. His initial growth was slow, along the 2nd centile, length 25th centile, and head circumference 0.4th centile at 8 months of age. At 2 months of age, ocular ultrasound examination demonstrated the eyes had axial lengths of 15.1 mm and 15.3 mm (average for age 16.5 mm). Flash visual evoked potentials and electroretinograms were elicited from both left and right eyes. He developed a mild bilateral ptosis, early hearing problems and had narrow ear canals. His speech was delayed initially. At six years of age, his height was 107 cm (2nd centile), weight 16 kg (2nd centile), and head circumference 49 cm (0.4th centile). He had a relatively flat face with prominent chin and paucity of facial movements, small teeth, and unusual low set ears with slightly tilted earlobes and a bifid uvula. His cognitive abilities appear to be normal, considering his visual impairment.
Array CGH analysis revealed a de novo 19p13.2 microdeletion of between 46 kb (chr19:9,913,222-9,959,613) and 81 kb (chr19:9,896,892-9,978,107) (GRCh38/hg38) partially involving OLFM2 and COL5A3. The minimal deleted region is predicted to remove the first exon of two splice forms of OLFM2 (NM_058164.3 and NM_001304347.1) and part of the 3′ UTR of the final exon of COL5A3. In contrast, while the maximal deleted region is predicted to affect the same two exons of OLFM2, it also removes the final 26 exons of COL5A3 (Fig. 1a) . Long-range PCR across the region failed to generate a product (data not shown). G-banded chromosome analysis detected a de novo balanced reciprocal translocation between chromosomes 3 and 13 (46,XY,t(3;13)(p23;q32)dn), and detailed array CGH did not reveal any copy number variation in the regions involved in the translocation. Parental karyotyping was normal and targeted array CGH of the deleted region showed no copy number variation. As the translocation was balanced, the deletion was considered more likely to be relevant to ocular phenotype. In addition, after panel sequencing of 546 known and candidate eye development genes using a new purpose designed gene panel, Case 1 was found to be heterozygous for a variant (rs143247685, NM_004380.2: c.2728A>G, p.Thr910Ala) in CREBBP, alterations in which can cause Rubenstein-Taybi syndrome 1. However, as this is a known polymorphism with a population frequency of 0.226%, is not located within a functional domain of the gene, and affects a non-conserved amino acid, it was deemed unlikely to affect the phenotype. No other plausible pathogenic variants were identified.
As OLFM2 is expressed in the human eye, associated with glaucoma, and zebrafish knockdowns demonstrate microphthalmia, with no comparable reports for COL5A3 suggesting a role in developmental eye anomalies, we prioritised OLFM2 and screened it for variants in our patient cohort.
Case 2
Case 2 is a male with unilateral microphthalmia with a unilateral cyst affecting the same eye and a contralateral coloboma, born to non-consanguineous parents at full term by normal delivery. His birth weight was 2.89 kg. He is registered blind, and has normal growth and cognitive development and no other medical issues. No causal variants were identified in SOX2 (Bakrania et al. 2007 ), OTX2 (Ragge et al. 2005) , SHH (Bakrania et al. 2010) , FOXE3 (Iseri et al. 2009 ), BMP4 (Bakrania et al. 2008 ), or BMP7 ) via a combination of Sanger sequencing, fluorescence in situ hybridisation (FISH) and Multiplex Ligation-dependent Probe Amplification (MLPA) analysis (data not shown), and his chromosome analysis was normal. We identified a novel single base substitution of c.-57C>G in the 5′ UTR of OLFM2 (see below).
Mutation analysis
OLFM2 is located on chr19:9,853,718-9,936,552 (GRCh38/ hg38), spans 82,835 bp, and comprises six exons. It has three splice forms with alternate first exons of 2019 bp (NM_058164.3), 1692 bp (NM_001304348.1), and 1993 bp (NM_001304347.1) encoding proteins of 454, 376, and 478 amino acids, respectively. A cohort of 258 patients was screened for variations in the exons and flanking intronic sequences, except NM_001304347.1 exon 1 (no working assay). We identified ten annotated variants, none reported pathogenic (ClinVar database); rs143959085, rs201189277, rs79341807, rs200752028, rs116666369, rs544945664, rs2303100, rs11556087, rs11556088, and rs34961482 (Supplementary Table 3 ). Of these, one was intronic (rs116666369) and four were synonymous (rs79341807, rs11556088, rs200752028, and rs3496148). One variant was in the 5′ UTR (rs544945664), but due to a minor allele frequency nearing 0.01, it was considered unlikely to have a pathogenic role. The remaining four variants were missense changes. However, rs2303100 and rs11556087 have minor allele frequencies greater than 0.01 (dbSNP147). In addition, while the minor alleles for rs201189277 and rs143959085 are rare, they are not predicted damaging by SIFT (http://sift.jcvi.org/) (Ng and Henikoff 2003) or PolyPhen (http://genetics.bwh.harvard.edu/pph/) (Adzhubei et al. 2010) and are in regions of limited conservation. rs201189277 was present in one individual with unilateral anophthalmia, now deceased, for whom parental DNA was unavailable. rs143959085 was identified in one individual with anophthalmia with contralateral normal eye, bronchiectasis, congenital heart disease, skeletal problems, undescended testes, umbilical hernia, inguinal hernia, and polydactyly of both hands, but was inherited from the asymptomatic father. Therefore, these variants were considered unlikely to contribute to the patient phenotypes. A previously unreported 5′ UTR c.-57C>G variant (chr19:9,936,451 [GRCh38/hg38]) was identified in Case 2, validated by Sanger sequencing, and inherited from his asymptomatic mother. Analysis using TFbind (http://tfbind. hgc.jp/) (Tsunoda and Takagi 1999) identified potential effects on transcription factor binding, including General Transcription Factor IIIA, Sp1 Transcription Factor, and Early Growth Response 3.
Luciferase assays
OLFM2 expression in Y79 cells was confirmed by PCR from cDNA. Two sets of triplicate transfection reactions were performed using plasmids containing wild type, mutant, or no inserts, and normalised to Renilla luciferase expression from a co-transfected pRL-TK plasmid containing no insert. A 21% decrease in expression from the mutant insert relative to wild type was identified (twotailed unpaired t test P = 0.0209) (Fig. 1b) .
In situ hybridisations
In situ hybridisations were performed on transverse sections of human CS15 and CS17 brain and eye tissue. At CS15, OLFM2 expression was observed in structures including the rhombencephalon, vagus, tissue surrounding the adenohypophyseal pouch, hypothalamus, otic vesicle, lens vesicle, and optic cup. At CS17, we observed expression in the lens vesicle, cerebral vesicle, spinal ganglion, ventricular zone, intermediate zone, marginal zone, and the tissue surrounding the diencephalic superventricle (Fig. 2a-m) .
Discussion
The identification of a de novo deletion affecting OLFM2 and COL5A3 in a boy with bilateral microphthalmia and sclerocornea led to a positional candidate gene approach to investigate OLFM2 in human eye development. We identified a further case with unilateral microphthalmia plus cyst and contralateral coloboma with an unannotated mutation in the 5′ UTR of OLMF2, which significantly decreases expression of OLFM2 in vitro. OLFM2 expression was demonstrated in multiple regions of the developing human embryo, including the lens vesicle and optic cup, but also primitive hypothalamus-pituitary axis, spinal ganglion, and otic vesicle.
Case 1 had a de novo deletion affecting OLFM2 and COL5A3. Although microdeletions spanning this region in other cases have been reported (Wong et al. 2007; Shaikh et al. 2009) , it is unknown whether affected individuals were screened for eye phenotypes. Given prior reports of the role of OLFM2 in developmental eye disease (Mukhopadhyay et al. 2004; Funayama et al. 2006; Lee et al. 2008) , we screened OLFM2 in our cohort of 258 patients with developmental eye anomalies.
The unannotated heterozygous substitution in the 5′ UTR of OLFM2 in Case 2 was predicted to alter transcription factor binding, and demonstrated a 21% decrease in in vitro expression. The asymptomatic status of the carrier mother suggests that this variant exhibits variable penetrance as often seen in eye development genes. The role of UTR and promoter variants in human disease is increasingly recognised. For example, a 5′ UTR substitution in PDE6H in a patient with cone dystrophy increases PDE6H expression leading to 4-5 times more protein, possibly resulting in cone degeneration by elevating cGMP in vivo (Piri et al. 2005) . Zhou et al. identified a novel heterozygous SOX2 3′ UTR variant in an individual with bilateral anophthalmia, suggesting that this may affect expression (Zhou et al. 2008) . Investigation of variants located within control regions of developmental eye genes is likely to provide an important source of causal changes and aid delineation of eye gene networks.
The potential contribution of Case 1′s deletion and Case 2′s unannotated variant to their phenotype is supported by the expression of OLFM2 in the developing human optic cup and lens vesicle. OLFM2 was also expressed in the developing ear, hypothalamic-pituitary axis, and other parts of brain and neural tube, which may partly explain the narrow ear canals, and reduced growth observed in Case 1. This indicates that more highly penetrant OLFM2 variants may cause wide-ranging phenotypes and could be important for developmental disorders affecting other structures. Findings, including the bifid uvula, may relate to effects of COL5A3, since this is seen in other collagen genes (Mark . The relatively mild phenotype observed in Case 2 is consistent with the moderate effect of the variant on expression and the modest reduction in eye size seen in zebrafish models (Lee et al. 2008) . OLFM2 may function by regulating transcription as an enhancer via the TGFβ cascade in eye development (Shi et al. 2014) and by interaction with PAX6 (Lee et al. 2008) . The TGFβ cascade has been implicated in eye development (Lovicu et al. 2011) , and PAX6 is a well-known control gene involved in this process (Hever et al. 2006) . Thus, alterations in expression caused by mutations may have cascading effects through these pathways. However, further variants within additional patient cohorts will be required to more accurately ascertain the range of phenotypes associated with changes in OLFM2.
Our investigations have not excluded the role of the partial COL5A3 deletion contributing to the phenotype of Case 1, which include a number of non-ophthalmologic features. COL5A3 is closely related to COL5A1, and encodes a protein that forms a heterotrimer with COL5A1 and COL5A2 to generate one form of type V collagen. In humans, COL5A3 is expressed in multiple tissues in both the adult and fetus, including multiple regions of the brain, while in 15.5dpc mice, it is primarily expressed in muscle, ligaments, and connective tissues (Imamura et al. 2000) . During zebrafish development, Col5a3 is expressed in the notochord, as well as the retinal pigment epithelium, and mesenchyme cells of the eye and lens (Fang et al. 2010 ). Therefore, it is possible that the loss of the 3′ end of COL5A3 may contribute to the eye phenotype of Case 1. In addition, both COL5A1 and COL5A2 (but not COL5A3) have been implicated in classical Ehlers-Danlos syndrome, a complex disorder with multiple phenotypes involving the connective tissue, including skin, eyes, ears, and teeth (Imamura et al. 2000; Hoffman et al. 2008 ) (OMIM #130000). This is of particular interest, as the Case 1 phenotype includes small low set ears with slightly tilted earlobes. Therefore, further investigation of the role of this gene is warranted.
In conclusion, we identify genetic variants of OLFM2 in two individuals with developmental eye disorders and reveal expression in the developing human eye, indicating that it is an important candidate for screening in other cohorts with developmental eye anomalies, and highlighting the importance of screening control regions both to identify causal variants and to aid understanding of the networks of genes involved in eye development.
